Introduction
Typical acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17)(q22-23;q12-21), 1 which fuses the promyelocytic leukemia (PML) and retinoic acid receptor ␣ (RARA) genes, and by its unique sensitivity to the differentiating action of all-trans retinoic acid (ATRA). [2] [3] [4] [5] This sensitivity is strongly associated with the expression of the PML/RARA transcript. 6, 7 The combination of ATRA and chemotherapy represents a major advance in the treatment of this disease. 6, 8 Rare APL cases involving RARA but not PML have been described, namely cases with t(11;17)(q23;q21), t(5;17)(q35;q21) and t(11;17)(q13;q21), in which RARA is fused respectively to the PLZF (promyelocytic leukemia zinc finger), 9, 10 NPM (nucleophosmin, B23) [11] [12] [13] and NuMA (nuclear mitotic apparatus) 14, 15 genes. The in vitro response to ATRA of these leukemic cells was investigated, in the hope that it might lead to a better understanding of the mode of action of ATRA.
APL cases with t(11;17) and expressing PLZF/RARA are resistant to ATRA, both in vivo and in vitro, 10, 16 except for one case reported with a good initial response to ATRA, G-CSF and chemotherapy. 17 The patient with t(11;17) and expressing NuMA/RARA underwent complete remission with ATRA alone, 14 but the in vitro response to ATRA was not analyzed. Finally, the clinical response to ATRA was difficult to evaluate in the first t(5;17) patient 11 and not reported for the second patient; 13 however, the in vitro response was recently reported as positive in this journal for the first patient. 18 We have previously described a case of atypical APL with an unbalanced t(5;17). Molecular analysis revealed a rearrangement of the RARA gene, with a breakpoint in the second intron, and no involvement of either PML or PLZF. 19 Given the presence of a chromosome 5q breakpoint, we searched for the presence of NPM/RARA transcripts and NPM rearrangement. As the clinical response to ATRA was difficult to evaluate, we investigated the in vitro response of the patient blast cells, as well as their PML and RARA immunofluorescence staining patterns.
Patient and methods

Patient
A 76-year-old woman, was referred to our institute for fever, wrist pain and asthenia lasting for 1 week. Neither clinical nor biological signs of disseminated intravascular coagulation were present. White blood cell count was 60 × 10 9 /l, platelet count was 90 × 10 9 /l and hemoglobin level, 90 g/l. Bone marrow smears revealed 70% blast cells. Most blasts had a classical acute myeloid leukemia (AML)-M3 morphology, but a minority was closer to the AML-M2 type, according to the FAB classification. 20 Major dysgranulopoiesis was observed. Immunophenotype was characteristic of APL: CD34 and HLA-DR negative, CD13 and CD33 positive. The patient received cytosine arabinoside (100 mg/m 2 from days 1 to 7) and daunorubicin (8 mg/m 2 from days 1 to 5) together with ATRA (45 mg/m 2 ). As she developed an ATRA syndrome on day 4, ATRA was discontinued and corticoids were given. She died on day 14 with septicemia and 90% blast cells in bone marrow. The cytogenetic analysis at diagnosis showed a der(5)t(5;17)(q?;q12-21) in all metaphases. The cytogenetic breakpoint on 5q was difficult to specify as the other derivative chromosome was absent and the translocation could have occurred on a del(5 q) related to the dysgranulopoiesis. Molecular analysis demonstrated a rearrangement of the RARA gene, with a breakpoint in the second intron, and no involvement of either PML or PLZF. 19 
RNA and DNA preparation, Southern blot and RT-PCR
DNA and total RNA were prepared by classical methods. 21 For Southern blotting a NPM cDNA clone (a kind gift of F Bullrich and C Croce, Kimmel Cancer Center, Philadelphia, PA, USA), 22 which is missing the first 50 nucleotides on the 5Ј side, 12 was used as a probe. RT-PCR was performed using the standard Perkin Elmer (Forest City, CA, USA) RT kit and protocol, starting from 1 g of total RNA. Thirty amplification cycles were performed; annealing temperature was 50°C. For semi-nested PCR, 1/10 of the primary PCR product was used in 20 reamplification cycles. Oligonucleotide sense primers were NPM1 (5Ј-TCGGTTGTGAACTAAA-GGCC-3Ј, nucleotide positions 139-158 of NPM/RARA fusion gene), NPM2 (5Ј-AGGCAAT-GAATTACGAAGGC-3Ј, positions 271-290), and NPM5Ј (5Ј-CCTTGGGGGCTTTGAAATAACACC-3Ј, positions 347-370). Antisense primers were RARA5 (5Ј-CCATCGTGGTAGC-CTTGAG-3Ј, positions 688-667) and RARA8 (5Ј-CAGAACTGCTGCTCTGGGTCTCAAT-3Ј, positions 591-567). Several controls for RNA integrity were performed including one with two oligonucleotides spanning exon 8, at respective positions 1113-1132 (5Ј primer), and 1274-1255 (3Ј primer). PCR reaction was for 30 cycles; annealing temperature was 55°C. Primer combinations and sizes of the expected products are detailed in Figure 1 .
Cell culture and differentiation assays
The patient's leukemic cells were thawed out and resuspended in RPMI 1640 medium supplemented with 15% FCS and antibiotics at a concentration of 10 6 cells/ml. Leukemic cells from two t(15;17)-positive APL, one case of AML-M1 with normal karyotype, the HL60 cell line, and the retinoic acid-sensitive NB4 cell line, 23 were used as controls. ATRA (Sigma, St Louis, MO, USA) was added to NB4 cells and patient cell cultures at a 10 −6 m final concentration. Cytospin preparations were made on glass slides at day 0 and after incubation for 3, 5 and 7 days.
Morphological differentiation was assessed by standard criteria (nucleus/cytoplasm ratio, nuclear shape, cytoplasmic granulations, and basophilia) on May-Grü nwald-Giemsa stained cytospin slides. Functional maturation, ie induction of NADPH oxidase activity, was assessed by the nitroblue tetrazolium (NBT) reduction test (0.1% NBT) in the presence of phorbol myristate acetate (PMA; Sigma) as described. 24, 25 A minimum of 200 cells was scored under light microscopy to determine the percentage of cells containing intracellular reduced black formazan deposits.
Immunofluorescence staining
Immunofluorescence staining was performed as previously described. 25 The first antibodies were either an anti-PML monoclonal antibody (mAb) (PG-M3, directed against the aminoterminal cysteine-rich domain of PML (aa 37-51), 26 used at a 1:10 dilution) or a rabbit anti-RARA antibody (antibody 115, directed against the carboxyterminal F region of RARA (a kind gift of C Egly and P Chambon, IGBMC, Strasbourg, France), used at a 1:1000 dilution). The secondary antibodies were either FITC-conjugated sheep anti-mouse IgG (Boehringer Mannheim, France), or FITC-conjugated donkey anti-rabbit IgG (Jackson Immunoresearch Laboratory, West Grove, PA, USA), used at a 1:50 dilution for the respective detection of the PML and RARA antibodies. Slides were counterstained with propidium iodide and mounted in antifade (Vectashield Vector Laboratories, Burlingame, CA, USA).
Results and discussion
RARA appears able to rearrange with alternative partner genes to produce leukemic cells with an APL phenotype. In the two cases of t(5;17) APL reported to date, RARA is rearranged with NPM. [11] [12] [13] Our case presented with a breakpoint on chromosome 5 q and RARA was rearranged, 19 which led us to look for the possible involvement of NPM. In a series of nested RT-PCR experiments using different primer combinations, we found no detectable expression of a NPM/RARA transcript, similar to that detected in the t(5;17). 12 Controls for RNA integrity, and cDNA amplification were all positive (Figure 1) . Southern blot revealed that the NPM gene was in germ line configuration (data not shown). The der(5)t(5;17) we analyzed here is thus molecularly different from the t(5;17) described previously. 12, 13 We are currently trying to identify the partner gene of RARA in this translocation.
The clinical response to ATRA of our patient was difficult to evaluate: ATRA was discontinued at day 4, and the patient died at day 14 with 90% blast cells in the bone marrow. We investigated the in vitro response of the patient blast cells in the presence of 10 −6 m ATRA, the highest dose used in such experiments. 4 After 5 day culture with ATRA, morphological maturation was observed in the t(15;17)-positive cases and NB4 cell line controls as more than 90% of the cells were at the metamyelocyte and band cells stage (Figure 2a ATRA) presented with a slight maturation, that is discrete decrease of cytoplasmic basophilia, number of granules and nucleus/cytoplasmic ratio (Figure 2c and d) after either 5-or 7-day culture. Thus, no terminal maturation was obtained in the patient blast cells.
Functional maturation was assessed by the NBT reduction test, as illustrated in Figure 3 . Time course of analysis is shown in Figure 4 . On day 0, 0-1% positive cells were detected in NB4 cells, in control t(15;17) APL and AML-M1 cells, whereas 12 and 13% positive cells, respectively, were observed in the patient cell cultures without or with ATRA. After 5 day culture with ATRA, only 83% of the patient cells showed black formazan deposits, vs 100% in NB4 cells, 96% in the t(15;17)-positive APL and 1% in the AML-M1 cells. On the same day, 75% of the patient cells reduced NBT without ATRA. The patient cells therefore presented with an atypical partial and spontaneous NBT reduction, which was seen throughout the experiment's time course.
Taken together, these results indicate that in vitro response to ATRA of the patient cells cannot be considered as positive, and that both morphological and functional maturation assays including appropriate controls are required for a meaningful interpretation of in vitro ATRA response. In the first t(5;17) case expressing NPM/RARA, the clinical response to ATRA was difficult to evaluate because ATRA, given in partial remission, did not prevent relapse. 11 In vitro experiments showed that only 75% of the leukemic cells reduced NBT, which is below the 95-100% rate reported for ATRA-sensitive cells. 4 But the response was considered as positive because: (1) NBT reduction was observed only in the presence of ATRA; and (2) ATRA induced a clear morphological maturation (over 90% of mature neutrophils). With regard to the t(11;17) APL expressing PLZF/RARA, no morphological maturation was observed with 10 −7 and 10 −6 m ATRA in the three cases studied. 10 Interestingly, a clinical and biological response to ATRA combined with G-CSF has recently been reported in a t(11;17) case expressing PLZF/RARA. 27 In normal cells, the PML protein is located in distinct nuclear structures called PML oncogenic domains (PODs) or nuclear bodies (PML NBs). They are disrupted in PML/RARA expressing leukemic cells [28] [29] [30] leading to a microspeckled immunostaining pattern predictive of a positive response to ATRA. [31] [32] [33] We investigated the localization of the PML protein in the patient cells by immunofluorescence with anti-PML mAb PG-M3. 33 In observed both with (Figure 5c and e) and without ATRA (Figure 5d) . Localization of the RARA protein was also investigated. Immunofluorescent staining with anti-RARA antibody 115 shows a microspeckled nuclear staining pattern 30, 34 in NB4 cells and in t(15;17)-positive APL cases without ATRA treatment (Figure 6a ). This pattern is similar to that observed with anti-PML mAb and corresponds to the PML/RARA protein and to the disruption of PML nuclear bodies. In contrast, a very faint, diffuse staining is observed in the patient as in HL60 cells and control AML-M1 cells (Figure 6b and c) . The staining patterns of the patient cells are therefore typical of non-PML/RARA AML cells. [28] [29] [30] [31] Such patterns were also observed in other non-responsive APLs such as PLZF/RARA t(11;17) cases, 35 and an ins(17;15) case expressing exclusively the reciprocal RARA/PML transcript. 25, 36 However, the NuMA/RARA t(11;17) case, which showed a clinical response to ATRA, and the second t(5;17) case expressing NPM/RARA, presented with a macrospeckled PML immunofluorescence pattern. 13, 15 Among APLs, PML nuclear bodies are disrupted in the PML/RARA-positive cases, but appear intact in PLZF/RARA, NuMA/RARA and NPM/RARA expressing cases, as in our patient. Disruption of PML bodies is therefore not required for an APL morphology or for ATRA responsiveness.
It was recently demonstrated that both the PML/RARA and PLZF/RARA products interact with the nuclear receptor tran- scriptional co-repressors (N-CoR or SMRT and mSin3A) and histone deacetylase, inhibiting the RARA targeted genes involved in cell differentiation. But unlike that of PML/RARA, the interaction between PLZF/RARA and N-CoR is ATRA insensitive (Refs 37-40 and 41, for review), a result offering a molecular basis for the differences observed in ATRA sensitivities. New therapeutic approaches using either arsenic trioxide (for review, Ref. 42) or histone deacetylase inhibitors 37, 39, 40 could be useful in the treatment of ATRA-resistant APLs.
